Literature DB >> 16893991

Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assay.

Rocio D Marchese1, Neil T Jain, Joseph Antonello, Laura Mallette, Kristin L Butterfield-Gerson, Jennifer Raab, Pamela Burke, Cheryl Schulman, Hilary Adgate, Daniel J Sikkema, Narendra Chirmule.   

Abstract

The Merck pneumococcal (Pn) enzyme-linked immunosorbent assays (ELISAs) for measuring antibodies to 12 serotypes (serotypes 1, 3, 4, 6B, 7F, 8, 9V, 12F, 14, 18C, 19F, and 23F) were validated in 1999. Merck Laboratories developed the Pn assays using 10 microg/ml C polysaccharide, 100 microg/ml Pn polysaccharide (PnPs) 25, and 100 microg/ml PnPs 72 for preadsorption of samples, standards, and controls in order to improve the specificity to the Pn serotypes in the vaccine. The Pn assays utilize postimmunization sera obtained from subjects immunized with PNEUMOVAX 23 as standards for measuring immunoglobulin G concentrations in sera obtained from vaccine clinical trials with adults and infants. This material was calibrated to the Pn reference standard serum, 89SF, subjected to the Merck Pn ELISA adsorbants. Comparisons were made between the Merck Pn assay and the international Pn assay, showing moderate agreement between the two assay formats. This work describes the test procedures and operating characteristics of the Merck Pn assays and the results of experiments performed to compare the Merck Pn ELISAs to the international Pn ELISAs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893991      PMCID: PMC1539118          DOI: 10.1128/CVI.00014-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  16 in total

1.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

Authors:  J W Findlay; W C Smith; J W Lee; G D Nordblom; I Das; B S DeSilva; M N Khan; R R Bowsher
Journal:  J Pharm Biomed Anal       Date:  2000-01       Impact factor: 3.935

Review 2.  Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae.

Authors:  C M Snapper; Y Shen; A Q Khan; J Colino; P Zelazowski; J J Mond; W C Gause; Z Q Wu
Journal:  Trends Immunol       Date:  2001-06       Impact factor: 16.687

3.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Authors:  B D Plikaytis; D Goldblatt; C E Frasch; C Blondeau; M J Bybel; G S Giebink; I Jonsdottir; H Käyhty; H B Konradsen; D V Madore; M H Nahm; C A Schulman; P F Holder; T Lezhava; C M Elie; G M Carlone
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 4.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

6.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination.

Authors:  M Koskela
Journal:  Pediatr Infect Dis J       Date:  1987-06       Impact factor: 2.129

8.  A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques.

Authors:  G Schiffman; R M Douglas; M J Bonner; M Robbins; R Austrian
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.

Authors:  G Vitharsson; I Jónsdóttir; S Jónsson; H Valdimarsson
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

10.  Natural and vaccine-related immunity to Streptococcus pneumoniae.

Authors:  D M Musher; A J Chapman; A Goree; S Jonsson; D Briles; R E Baughn
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

View more
  9 in total

1.  Development and characterization of a multiplex bead-based immunoassay to quantify pneumococcal capsular polysaccharide-specific antibodies.

Authors:  David L Klein; Joseph E Martinez; Michael H Hickey; F Hassouna; K Zaman; Mark Steinhoff
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

2.  Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen.

Authors:  Michael D Raedler; Samantha Heyne; Erica Wagner; Sheri K Shalkowski; Susan Secore; Annaliesa S Anderson; James Cook; Leslie Cope; Tessie McNeely; Mary Retzlaff; Jon Shanter; Leonard J Rubinstein; Tina Green; N Kartsonis; Mark T Esser
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

3.  Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.

Authors:  Karen Ciprero; Kirill A Zykov; Nikolay I Briko; Tulin Shekar; Tina M Sterling; Elizaveta Bitieva; Jon E Stek; Luwy Musey
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

4.  Evaluation of the specificity of pneumococcal polysaccharide enzyme-linked immunosorbent assay and the effect of serum adsorption based on standard pneumococcal serogroup- or serotype-specific rabbit antisera.

Authors:  Hans-Christian Slotved; Christina Guttmann; Charlotte Demuth Pedersen; Jasper Neergaard Jacobsen; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2009-07-08

5.  Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Authors:  Karen L Ciprero; Rocio D Marchese; Patrick Richard; Martine Baudin; Tina M Sterling; Susan B Manoff; David Radley; Jon E Stek; Benoît Soubeyrand; John D Grabenstein; Sandrine I Samson; Luwy K Musey
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

6.  Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum.

Authors:  Rocio D Marchese; Derek Puchalski; Pamela Miller; Joseph Antonello; Olivia Hammond; Tina Green; Leonard J Rubinstein; Michael J Caulfield; Daniel Sikkema
Journal:  Clin Vaccine Immunol       Date:  2009-01-21

7.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

8.  The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency.

Authors:  Lisanne M A Janssen; Michiel Heron; Jean-Luc Murk; Alexander C A P Leenders; Ger T Rijkers; Esther de Vries
Journal:  Clin Exp Immunol       Date:  2021-06-01       Impact factor: 4.330

9.  Autologous Splenocyte Reinfusion Improves Antibody-Mediated Immune Response to the 23-Valent Pneumococcal Polysaccharide-Based Vaccine in Splenectomized Mice.

Authors:  Shengwen Calvin Li; Mustafa H Kabeer
Journal:  Biomolecules       Date:  2020-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.